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Pseudomonas aeruginosa lung infections present a major challenge to healthcare systems worldwide because they are commonly
associated with high morbidity and mortality. Here, we demonstrate the protective efficacy of type a and b flagellins (bivalent
flagellin) against acute fatal pneumonia in mice. Mice immunized intranasally with a bivalent flagellin vaccine were challenged
by different flagellated strains of P. aeruginosa in an acute pneumonia model. Besides the protective effect of the vaccine, we
further measured the host innate and cellular immunity responses. The immunized mice in our study were protected against
both strains. Remarkably, active immunization with type a or b flagellin significantly improved survival of mice against
heterologous strain compared to flagellin a or b antisera. We also showed that after an intranasal challenge by P. aeruginosa
strain, neutrophils are recruited to the airways of vaccinated mice, and that the bivalent flagellin vaccine was proved to be
protective by the generated CD4+IL-17+ Th17 cells. In conclusion, bivalent flagellin vaccine can confer protection against
different strains of P. aeruginosa in an acute pneumonia mouse model by eliciting effective cellular and humoral immune
responses, including increased IL-17 production and improved opsonophagocytic killing.
1. Introduction
Pseudomonas aeruginosa pulmonary infection as a life-
threatening complication frequently causes bacteremia
and sepsis in hospitalized and immunocompromised
patients [1, 2]. Moreover, the widespread and empirical
use of broad-spectrum antibiotics in critical care units
has led to the continuous emergence of multidrug-
resistant (MDR) P. aeruginosa strains that present a major
challenge to clinical therapy and contribute significantly to
increased morbidity and mortality [3]. The high mortality
and prevalence of infection with MDR P. aeruginosa
strains accompanied by the paucity of new effective antibiotic
classes present unique challenges to clinicians and highlight
the necessity for designing new treatment approaches, such
as immunotherapy, which targets pathogen-specific viru-
lence factors to reduce pathogenesis without inducing
multidrug resistance [4, 5]. Moreover, the complexity of
the P. aeruginosa genome, which encodes numerous anti-
gens, indicates that immunotherapy using a single antigen
will not provide sufficient protection.
To date, most P. aeruginosa vaccines focusing on
immunization and treatment targeting pseudomonal viru-
lence factors, such as LPS O antigen [6], the outer mem-
brane proteins F and I [7], or the type III secretion
system component PcrV [8], have been described in the
literature as having conventional protective mechanisms,
namely, antibody-mediated opsonophagocytic killing and/
or antibody-mediated toxin inhibition. Recently, studies
have shown that Th17 cells are critical for providing
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protection against P. aeruginosa pneumonia via rapid
recruitment of neutrophils to the airways in the absence of
opsonophagocytic antibody [9, 10]. These findings suggest
that an effective vaccine for providing full-fledged protection
against various P. aeruginosa infections in different tissues
can induce multiple cellular and humoral effectors.
Most clinical isolates of P. aeruginosa are motile with the
aid of a single polar flagellum, which is essential for systemic
spread throughout the organs from the initial site of coloni-
zation [11]. Flagellin is the primary protein component of
the flagella, which is classified into two distinct serotypes a
and b [12]. Furthermore, the conserved domains of flagellin
are strongly antigenic and serve as a pathogen-associated
molecular pattern (PAMP) that induce a strong NFκB-medi-
ated inflammatory response via toll-like receptor 5 (TLR5)
signal transduction [13]. Several studies have shown the
strong immunogenicity of flagellin initiates a general
recruitment of both T and B cells to secondary lymphoid
sites, eliciting TLR5+, CD11c+, and T cell-like similar antigen
recognition [14, 15]. Due to TLR5 agonist activity of flagellin,
they play an important role as potent adjuvants to enhance
protective humoral responses [15, 16]. Several in vivo studies
not only have demonstrated the importance of flagellins as a
crucial virulence factor contributing to the pathogenesis of
lung infections but also validated them as target antigens
for immunization [17–22]. Immunization with type a or b
flagellin provided protection against lung infections [23],
keratitis [24], urinary tract, and burn wound infections
[25]. These studies have confirmed that protection provided
by flagellin is highly type specific and the presence of both
types of flagellin is crucial. The results of our recent stud-
ies [20, 26] demonstrating protection provided by flagellin
in P. aeruginosa burn infection via induction of IL-17
encouraged us to study active and passive immunization
strategies using bivalent flagellin in order to provide full-
fledged protection against various P. aeruginosa clinical
isolates in the acute fatal pneumonia model.
2. Materials and Methods
2.1. Bacterial Strains. P. aeruginosa strains PAK and PAO1
were used for the purification of type a and b flagellin pro-
teins, respectively.
2.2. Animals. Female 6–8-week-old BALB/C mice were pur-
chased from Pasteur Institute (Tehran, Iran). All animal
experiments were complied with institutional animal care
committee (IACC) guidelines regarding the use of animals
in research.
2.3. Preparation of Recombinant Proteins. Recombinant
type a and b flagellin proteins were purified from E. coli
BL21 (DE3) carrying pET-28a vector as previously
described [27, 28].
2.4. Immunization of Mice. Mice were immunized intrana-
sally (i.n.) as described previously. Briefly, mice were anes-
thetized by mixture of ketamine (6.7mg/ml) and xylazine
(1.3mg/ml) and then immunized by placing 10μl of mixed
flagellins (1μg of each flagellin), or flagellin a (2μg), or
flagellin b (2μg), or PBS on each nostril at weekly intervals.
In several published P. aeruginosa vaccine studies, PBS has
been used as a control [9, 29–31]. At day 42, mice were chal-
lenged i.n. with 2× 107CFU of P. aeruginosa strains directly
into each nostril, as described previously [23]. In addition,
five mice from each group were sacrificed 24 h after infection.
Then the lung, liver, blood, and spleen were harvested for
bacterial load enumeration. Bronchoalveolar lavage fluid
(BALF) was collected 6 and 18 h after infection for quantita-
tion of CFU, neutrophils, and IL-17 cytokine. For passive
immunization, mice were injected intraperitonealy (i.p.) with
200μl of antibodies raised to bivalent flagellin, or flagellin a,
or flagellin b 12 h before and after challenge. All mice were
closely monitored for one week.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA). To
determine the levels of specific antibodies (total IgG, IgG1,
and IgG2a) in mouse sera, ELISA was performed with plates
coated with a whole live cell of P. aeruginosa strains PAK or
PAO1 or mixed flagellins as described previously [20].
Briefly, 100μl of either P. aeruginosa strains PAK or PAO1
or mixed flagellins was incubated overnight at 4°C, washed
with 0.5% Tween-PBS (T-PBS), and blocked with PBS+3%
bovine serum albumin (Sigma-Aldrich). Indicated dilutions
of sera from immunized mice were incubated overnight at
4°C and washed 3x with T-PBS, and 100μl of 1 : 7000-diluted
horseradish peroxidase-conjugated goat anti-mouse (HRP;
Sigma-Aldrich) was incubated (1 h, RT). Plates were then
washed five times with T-PBS, and of TMB substrate
(Sigma-Aldrich) was added (100μl/well; 30min. at RT).
Concentrations of serum IgG1 and IgG2a subtypes against
mixed flagellins were determined as described above, except
that we used 100μl/well of IgG subtype-specific HRP-
conjugated secondary anti-mouse IgG1, or IgG2a antibody
(Sigma-Aldrich) diluted 1 : 8000 in 0.5% skim milk/T-PBS.
2.6. Cell Proliferation and Cytokine Measurements. For lym-
phocyte proliferation assays, ELISA plates were seeded with
1× 105 T cells, 1× 105 irradiated (1500 rad) splenocytes iso-
lated from naïve mice as antigen-presenting cells (APCs),
and 1μg of flagellin a, or flagellin b as antigen, while other
groups contained 1 μg per well anti-CD4, anti-CD8, and rat
IgG isotype (all are from BD Biosciences) antibody. The cells
were all cultured in RPMI 1640 containing 10% heat-
inactivated FBS. At 24h and 72 h after incubation, T lympho-
cyte proliferation assay was carried out using 5-bromo-2-
deoxyuridine (BrdU; Roche, Germany) according to the
manufacturer’s protocol. At the same time, IL-17 levels were
measured by examining cell-free culture supernatant fluid
using specific ELISA assay (R&D Systems).
2.7. Depletion of Immune Effectors. Immune cell subsets were
depleted as described [32]. For in vivo CD4 or CD8 T cells, T
cell depletion, CD4-specific mAb (GK1.5; BD PharMingen),
or CD8-specific mAb (53-6.7; BD PharMingen) were admin-
istered both intranasally and intraperitoneally (100μg/dose
and 500μg/dose, resp.) 72 and 24 hours before bacterial chal-
lenge. Depletion of the targeted cell types was confirmed by
subsequent FACS analysis, which showed >98% depletion
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of the respective cell type. Polyclonal antibody to murine IL-
17 was produced by immunizing rabbits at multiple intrader-
mal sites with mouse recombinant IL-17 (R&D Systems)
mixed with CFA, as previously described [33]. Affinity chro-
matography (using protein G) was used for the separation of
anti-IL-17 IgG from the whole serum, according to the man-
ufacturers’ instructions (Thermo Fisher Scientific, USA).
This antibody was specific for IL-17, as determined by
ELISA, but did not cross-react IL-2, IFN-γ, IL-4, IL-10,
IL-5, or IL-13. The control antibody used in these experi-
ments was the IgG fraction from normal rabbit serum puri-
fied by protein G affinity chromatography, as described
above. IL-17 depletion studies were done using anti-IL-
17 IgG (1mg i.p.) or control IgG for 3 consecutive days
before the mice were challenged by P. aeruginosa strains
as described by Li et al. [34].
2.8. Opsonophagocytic Activity Assay. The assay was per-
formed as described [20, 25]. Briefly, assays were performed
in a sterile microcentrifuge tube 100μl of each component,
polymorphonuclear leukocytes (PMNs; 2× 109 cells), P. aer-
uginosa strains (5× 107CFUs), infant rabbit serum, and
diluted antibodies. Generally, ≥50% opsonic killing activity
of immune serum is considered biologically significant [10].
2.9. Motility Inhibition Assay. Assays were performed as
described [20, 25]. Briefly, antibodies were added to motility
agar (LB with 0.3% (w/v) agar) in 24-well plates (Greiner
Bio-One, Germany). P. aeruginosa strains (OD600 = 0.2)
were added into the central well of each plate and incubated
at 37°C. Mean diameters of bacterial colonies with sharp
and less distorted rings were measured after incubating for
18 h.
2.10. Statistical Analysis. All statistical analyses were per-
formed using GraphPad Prism 6 (GraphPad Software Inc.,
USA). Nonparametric data were analyzed by Kruskal-
Wallis followed by Dunn’s multiple comparison tests.
Parametric data were evaluated by ANOVA with Tukey’s
multiple comparison tests. All results were expressed as
the mean± standard deviation (SD). The log-rank test
was used to compare Kaplan-Meier between different treat-
ment mouse groups. P value of <0.05 was considered
statistically significant.
3. Result
3.1. Protective Efficacy of Bivalent Flagellin Immunization. To
determine the protective efficacy of the bivalent flagellin vac-
cine against P. aeruginosa strains, immunized mice were
challenged i.n. with different flagellated strains of P. aerugi-
nosa. As shown in Figures 1(a) and 1(b), nasal immunization
with bivalent flagellin protected against lethal pneumonia
due to PAK (100% survival) and PAO1 (91.66% survival)
and survival rates were all significantly higher than those in
mice administered with PBS (P > 0 01). Flagellin a-
immunized mice were significantly protected (P > 0 05) from
lethality after challenge with homologous strain PAK with a
survival rate of 91.66%, compared to 58.33% for heterologous
strain PAO1 (Figures 1(c) and 1(d)). Nasal immunization
with flagellin b leads to 83.33% protective effect for homolo-
gous strain PAO1 compared with 41.66% in the heterolo-
gous PAK challenge (P > 0 05; Figures 1(e) and 1(f)).
However, provided heterologous protection by flagellin a or
flagellin b immunization was significantly higher than that
of the controls.
Moreover, we evaluated the efficacy of passive immuniza-
tion with antisera from bivalent flagellin-, or flagellin a-, or
flagellin b-, or PBS-immunized mice against P. aeruginosa
strains. Bivalent flagellin antisera completely protected mice
from challenge with PAK (75% survival) and PAO1
(83.33% survival; Figures 1(a) and 1(b)). Transfer of flagellin
a antisera exhibited significant protective effect role against
homologous strain PAK (83.33% survival, P < 0 01) but only
has a partial protective role against heterologous strain PAO1
(25% survival, Figures 1(c) and 1(d)). Passive immunization
with flagellin b significantly protected immunized mice
against homologous strain PAO1 (75% survival, P < 0 01)
compared with heterologous strain PAK (16.66% survival,
Figures 2(e) and 2(f)). However, provided heterologous pro-
tection by antisera to flagellin a or flagellin b was significantly
higher than that of the controls (P < 0 05; Figures 1(c), 1(d),
1(e), and 1(f)).
3.2. Opsonic Killing Activity of Bivalent Flagellin Immune
Sera. To test the functional activity of serum antibodies in
the protection afforded by the bivalent flagellin vaccine, we
evaluated the in vitro opsonic killing activity of pooled sera
obtained from immunized mice 3 weeks after the third (final)
nasal immunization. As shown in Figure 3, bivalent flagellin
antisera at a dilution 1 : 10 significantly promoted the phago-
cytosis of P. aeruginosa strains PAK (82.70%) and PAO1
(86.23%) compared with that of serum isolated from control
group mice (P < 0 01). Flagellin a antiserum in the immune
serum showed significantly higher killing ability against
homologous strain PAK (78.61%, P < 0 01) in comparison
with PAO1 strain (33.56%, Figure 3). Sera from flagellin b-
immunized mice had significantly killing activity against
homologous strain PAO1 (80.59%, P < 0 01), comparable to
that against heterologous strain PAK (24.27%, Figure 3).
However, the opsonic killing activity of flagellin a or flagellin
b antisera against the heterologous strain was significantly
higher than that of serum from control mice (P < 0 05).
3.3. Antimotility Activity of Bivalent Flagellin Immune Sera.
We evaluated the functional activity of bivalent flagellin
immune sera to inhibit the motility of different flagellated
P. aeruginosa strains. As shown in Figures 4(a) and 4(b),
bivalent flagellin immune sera at a dilution of 1 : 300 or less
completely inhibited the motility of P. aeruginosa strains
compared with the controls (P < 0 01). Antisera to flagellin
a at dilution of 1 : 300 or less completely inhibited the motility
of the homologous strain (P < 0 01), but there was some
cross-reactivity with the heterologous strain (P < 0 05;
Figures 4(a) and 4(b)). Antibodies against flagellin b at dilu-
tion of 1 : 300 or less inhibited the motility of homologous
strain PAO1 more significantly than heterologous strain
PAK (P < 0 05; Figures 4(a) and 4(b)).
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3.4. Specificity of Antibodies Raised against Bivalent Flagellin.
To assess the humoral responses evoked by bivalent flagellin
vaccine, we compared serum IgG levels among immunized
mice challenged with either the PAK or PAO1 strain. While
the prechallenge IgG levels of mice injected with bivalent
flagellin against whole live cells of P. aeruginosa strains or
mixed flagellins were similar, the serum IgG levels signifi-
cantly increased after infection with PAK or PAO1 strains
infection (P < 0 05; Figures 5(a), 5(b), and 5(c)). IgG titer in
sera from vaccinated mice with type a or b flagellin signifi-
cantly increased after challenge with the homologous strain
compared with that in heterologous strain of P. aeruginosa
infection (P < 0 01; Figures 5(a), 5(b), and 5(c)). Similar
results were obtained when IgG1 subtype was examined
(Figure 5(d)). Among bivalent flagellin-immunized mice,
no significant differences in the titer increases for specific
IgG2a subtypes against mixed flagellins were observed in
pre- and postchallenge with PAK or PAO1, respectively
(P > 0 05; Figure 5(e)). IgG2a level in mice immunized
with type a or b flagellin was significantly decreased after
challenge with the heterologous strain compared with
mice challenged with the heterologous strain (P < 0 05;
Figure 5(e)). The titer of antigen-specific antibodies
induced by bivalent flagellin was similar to that induced
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Figure 1: Survival rates of actively and passively immunized BALB/c mice (n = 12mice/group) to infection with P. aeruginosa strains. Active
and passive immunization against bivalent flagellin (a, b), flagellin a (c, d), and flagellin b (e, f). Kaplan-Meier curves were plotted for mice of
the above groups, which were challenged by 2× 107 CFUs of P. aeruginosa strains PAO1 and PAK and monitored the seven day survival rates.
∗P < 0 05 and ∗∗P < 0 01.
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by flagellin a or b, which indicated that there is no inter-
ference among each vaccine component in induction of
protective antibodies (data not shown).
3.5. T Cell Responses Induced by Bivalent Flagellin Vaccine.
To test whether vaccine candidates could induce lymphocyte
proliferation, we analyzed the stimulation index of splenic T
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Figure 2: The protective role of CD4+ T lymphocytes in bivalent flagellin vaccine against P. aeruginosa strains. Bivalent flagellin- (a, b),
flagellin a- (c, d), and flagellin b- (e, f) immunized mice (n = 12 mice/group) were treated with either anti-CD8 monoclonal
antibody, or anti-CD4 monoclonal antibody, or normal rat IgG and then were challenged with 2× 107 CFUs of P. aeruginosa strains
PAO1 and PAK. ∗P < 0 05 and ∗∗P < 0 01. NS = nonsignificance.
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cells from immunized mice. As shown in Figures 6(a) and
6(b), there was a higher proliferation level of bivalent flagellin
immune T cells to either flagellin a or flagellin b at both
24 and 72 h when compared with T lymphocytes isolated
from the controls (P < 0 01), which means vaccinated T lym-
phocytes could be stimulated by both types of flagellin with-
out interference. (Figures 6(a) and 6(b); P < 0 05). The
proliferation rate of flagellin a or b immune T cell cultures
stimulated with the homologous antigen at both 24 and
72 h was significantly higher than the cultures stimulated
with heterologous antigen (Figures 6(c) and 6(d) and
Figures 6(e) and 6(f); P < 0 01). Additionally, the prolifera-
tion level of flagellin a or b immune T cell cultures stimulated
with heterologous antigen was significantly higher than T
cells from control mice (Figures 6(c) and 6(d) and
Figures 6(e) and 6(f); P < 0 05).
In order to further distinguish whether CD4+ T lympho-
cytes were the immune cells involved in the anti-infection
effect by bivalent flagellin vaccine in vivo, CD4+ or CD8+ T
lymphocytes were depleted independently by corresponding
antibodies as described above. We demonstrated that anti-
infection activity with the bivalent flagellin immunization
relatively abrogate in in vivo depletion of CD4+ T lympho-
cytes. After depletion of CD4+ T lymphocytes in the bivalent
flagellin-immunized group, the survival rate decreased to
50% and 41.66% when infected with strain PAK and PAO1,
respectively (Figures 2(a) and 2(b)). Also, the survival rate
was not decreased compared to the control group when chal-
lenged by PAK (Figure 2(a)) and PAO1 (Figure 2(b)), since
the killing ability of immune serum against P. aeruginosa
strains was effective. Depletion of CD4+ T lymphocytes in fla-
gellin a-immunized group decreased the survival rate to 50%
and 16.16% when challenged with strain PAK and PAO1,
respectively (Figures 2(c) and 2(d)). The survival rate of mice
in flagellin b-immunized group after depletion of CD4+ T
lymphocytes decreased to 41.66% and 0% when challenged
with the strain PAO1 and PAK, respectively (Figures 2(e)
and 2(f)). Depletion of CD8+ T lymphocytes showed no
effect on the survival rate of immunized mice. Also, the
treatment with normal rat IgG showed no effect on the
survival rate.
3.6. Th17 Cells and IL-17Were Activated by Bivalent Flagellin
Vaccine. To test whether the bivalent flagellin vaccine could
induce IL-17, we evaluated IL-17 production by the CD4+
T cells recovered from immunized mice in the presence of
irradiated splenocytes and flagellin a or flagellin b. The levels
of IL-17 in the supernatants of the immunized T cells were
significantly higher than those of control T cells (P < 0 05,
Figures 7(a) and 7(b)). The presence of the anti-CD4 mono-
clonal antibody during coculture returned the IL-17 levels as
those of the control T cells, further indicating that CD4+ T
cells are the predominant source of IL-17 in this system
(Figures 7(a) and 7(b)). The IL-17 levels in the presence of
the anti-CD8 monoclonal antibody during coculture had no
significant difference between each group (Figures 7(a) and
7(b); P > 0 05). IL-17 production by flagellin a- or flagellin
b-immunized T cells when stimulated with the homologous
antigen was significantly higher than that of T cells stimu-
lated with heterologous antigen (P < 0 05; Figures 7(c) and
7(d) and Figures 7(e) and 7(f)). IL-17 production by flagellin
a- or flagellin b-immunized T cells when stimulated with
heterologous antigen was significantly higher than that of
the control T cells (P < 0 05; Figures 7(c) and 7(d) and
Figures 7(e) and 7(f)). Flagellin a- or flagellin b-immunized
T cells when stimulated with homologous or heterologous
antigen in the presence of the anti-CD4monoclonal antibody
during coculture returned the IL-17 levels as those of the con-
trol T cells. There was no significant difference between the
IL-17 levels of flagellin a or flagellin b among cultures treated
by either immunized T cells, anti-CD8 monoclonal antibody,
or control IgG (P > 0 05; Figures 7(c) and 7(d) and
Figures 7(e) and 7(f)). T cell proliferation and IL-17 secretion
response assays were confirmatory data showing the evi-
dence for a heterologous T cell response among immunized
flagellin a or b mice indicating an active clonal expansion
and a neutrophil response that lead to higher survival (pro-
tective) rates among immunized mice than control mice.
3.7. Bivalent Flagellin Vaccine Decreased P. aeruginosa
Strain Burden. In order to evaluate the protective efficacy
of bivalent flagellin vaccine, we determined the bacteria
number in the lung, liver, blood, and spleen of infected
immunized mice. Immunization with bivalent flagellin
reduced the PAK and PAO1 strain burden in the lung,
liver, blood, and spleen compared with mice injected with
PBS (P < 0 01; Figures 8(a), 8(b), 8(c), and 8(d)). Immuni-
zation with flagellin a significantly decreased homologous
strain PAK burden in the main organs and blood compared
with the heterologous strain PAO1 burden (P < 0 05;
Figures 8(a), 8(b), 8(c), and 8(d)). Immunization with fla-
gellin a significantly decreased homologous strain PAO1
burden in the main organs and blood compared with het-
erologous strain PAK burden (P < 0 05; Figures 8(a), 8(b),
8(c), and 8(d)).
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Figure 3: The opsonic killing activity of sera from bivalent flagellin-,
flagellin a-, and flagellin b-immunized mice 3 weeks after the final
immunization. Values presented as the mean of triplicate technical
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3.8. Neutrophil Recruitment to the Lungs of Bivalent Flagellin-
Immunized Mice. As IL-17 is a critical mediator for neutro-
phil recruitment to the lung, we evaluated the numbers of
neutrophils recruited to the airways in immunized mice. As
shown in Figures 9(a), 9(e), and 9(f), in bivalent flagellin-
immunized mice, the number of BALF neutrophils and IL-
17 levels at 6 h after the challenge were significantly more
than those of the controls (P < 0 05). At this point in time,
the bacteria numbers in the BALF of bivalent flagellin-
immunized were significantly lower than those of the con-
trols (P < 0 05, Figure 9(c)). IL-17 levels and neutrophil
numbers in BALF of the flagellin a- or b-immunized mice
obtained 6h after homologous challenge were significantly
higher than those in mice challenged with the heterologous
strain (P < 0 05; Figures 9(a), 9(e), and 9(f)). In flagellin a-
or b-immunized mice, IL-17 levels and neutrophil numbers
in BALF obtained 6h after challenge with the heterologous
strain were significantly higher than those in nonimmunized
mice (P < 0 05; Figures 9(a), 9(e), and 9(f)). At this point
in time, the heterologous strain numbers in the BALF of
flagellin a- or b-immunized mice were significantly lower
than those in mice challenged with the heterologous strain.
(P < 0 05, Figure 9(c)). At 18h after bacterial challenge, the
number of BALF neutrophils and bacterial CFU in bivalent
flagellin-immunized mice was significantly lower than that
of the controls (P < 0 05; Figures 9(b) and 9(d)). IL-17 levels
and neutrophil in BALF of the flagellin a- or b-immunized
mice obtained 18h after homologous challenge were signifi-
cantly higher than those in mice challenged with the heterol-
ogous strain (P < 0 05; Figures 9(b), 9(e), and 9(f)). At this
point in time, the heterologous strain numbers in the BALF
of flagellin a- or b-immunized mice were significantly lower
than those in mice challenged with the heterologous strain.
(P < 0 05, Figure 9(d)).
3.9. Effect of Neutralization of IL-17 on Protective Efficacy of
Bivalent Flagellin Vaccine. To further assess the protective
role of IL-17 in the bivalent flagellin vaccine efficacy, we
investigated the effects of neutralization of IL-17 prior to lung
challenge with P. aeruginosa strains. As shown in
Figures 10(a) and 10(b), mortality in the bivalent flagellin-
immunized mice which received anti-IL-17 IgG was signifi-
cantly higher than that given in the control IgG (P < 0 05).
In flagellin a-immunized group, the survival rate decreased
to 50% and 8.33% after receiving anti-IL-17 IgG when chal-
lenged with the strains PAK and PAO1, respectively
(Figures 10(c) and 10(d)). In flagellin b-immunized group,
the survival rate decreased to 41.66% and 0% after receiving
anti-IL-17 IgG when challenged with the strains PAO1 and
PAK, respectively (Figures 10(e) and 10(f)).
4. Discussion
Pulmonary infections due to P. aeruginosa have emerged as a
serious challenge for medical therapy, mainly due to the pau-
city of new effective antibiotic classes and high morbidity and
mortality [35]. This terrible situation has motivated attention
in the vaccine, a possible approach to combat P. aeruginosa.
In addition, the complex pathogenicity of P. aeruginosa and
the diverse function of its virulence factors represent major
obstacles to the development of effective universal vaccines
[36]. For full-fledged protection against various P. aeruginosa
infection, incorporation of innate and adaptive immune
system is crucial. In lung tissue, a combination of opsonizing
antibodies and inflammatory responses of the innate
immune cell is mediated full-fledged protection against P.
aeruginosa [34]. Thus, antigens in an effective vaccine against
P. aeruginosa infections should induce both humoral and
cellular immune responses. Although several P. aeruginosa
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antigens have so far been evaluated as P. aeruginosa vaccine
candidates, flagellin proteins hold a greatest promise because
these P. aeruginosa components evoke in vivo immune
responses which in turn promote opsonophagocytic activity
[25]. They are also vital for P. aeruginosa survival during
infection and are expressed by the majority of clinical P. aer-
uginosa strains [26]. Moreover, flagellin promotes marked
increases in T and B lymphocyte recruitment to secondary
lymphoid sites, increasing the likelihood of these cells
encountering their specific antigen, and can also directly
stimulate CD4+ and CD8+ T cells [14, 15].
Here, we have shown that bivalent flagellin vaccine pro-
vided significant homologous and heterologous protection
against fatal P. aeruginosa pneumonia and it was associated
with antiopsonophagocytic killing and antimotility activities
as well as an effector IL-17 cytokine response. Indeed, the
antiopsonophagocytic killing and antimotility activities pro-
vided by bivalent flagellin antiserum to blunt the pathogene-
sis and invasive progression of infection coupled with the
effector cytokines of Th17 cells augmented a broader
spectrum of protective activity against P. aeruginosa-induced
fatal pneumonia. Evaluation of various aspects of mouse
immune response and protective efficacy of the vaccine in a
murine acute pneumonia model indicated robust protection
against potentially lethal P. aeruginosa infections.
The cytokine secretion of splenic T cells indicated that
bivalent flagellin could induce efficient Th17 type cytokines
by antigen stimulation in combination with the findings that
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IgG1 and IgG2a subtypes in the serum of immunized mice
further confirm that flagellin evokes the development of
humoral and cell-mediated immune responses and acquires
greater efficacy than monovalent flagellin to provide protec-
tion against different flagellated strains of P. aeruginosa.
These data suggested that collaboration of CD4+ T cells with
the capacity to produce IL-17 and opsonic antibodies is
required for protective immunity against acute P. aeruginosa
pneumonia [37, 38]. The protective immune response fol-
lowing P. aeruginosa immunization of rats is associated
with CD4+ T cell-dependent immunity [39]. P. aeruginosa
immunization of mice pulsed DCs protecting mice against
pulmonary infection, depending on the presence of CD4+
T cells [38].
It must so be mentioned that IL-17 was recently shown to
be a critical factor in a vaccine that induced protection to P.
aeruginosa [10]. IL-17 mainly mediates its immune regula-
tory function by promoting the production of antimicrobial
peptides from lung epithelia or of proinflammatory cytokines
and chemokines, which leads to the attraction of neutrophils
and macrophages to the lung and the subsequently increased
phagocytosis of bacteria and enhanced clearance of infection
[9, 10, 40]. Early increased neutrophil number in bivalent
flagellin-immunized mouse lung tissue is associated with a
rapid reduction of bacterial load in lung tissue as well as in
homologous and heterologous protection. Our data suggest
that CD4+ T cells may be one of the sources of IL-17 during
acute pulmonary P. aeruginosa infection and could be a key
component of full immunity to lung infection by this patho-
gen [41, 42]. A recent study has shown that γδ T cells pro-
duced IL-17 in the lungs as early as 2 h after Bordetella
pertussis infection [43]. The level of IL-17 increased 6 h after
infection, demonstrating that acute pulmonary infection
with P. aeruginosa rapidly induced IL-17 production in the
lungs; this IL-17 may be involved in the innate immune
response to the infection [44, 45].
Also, T cells from nasally immunized mice with live-
attenuated P. aeruginosa vaccine show a high IL-17 levels
after antigen stimulation and high number of CD4+IL-
17+Th17 cells in the spleen at 6 h after challenge and medi-
ated protective immune responses [34]. Although the focus
of studies examining IL-17 production has largely been on
CD4+αβ T cells, γδ T cells have also been shown to be a
potent source of IL-17 and, in some cases, produce more
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IL-17 than αβ T cells [46–49]. Interestingly, it has been
shown that Th17 cells increase after 8 h of infection with P.
aeruginosa, and the level of IL-23 also increases in the acute
pulmonary P. aeruginosa infection [44]. Recent studies sug-
gest that IL-23 promotes the Th17 cell development from
effector memory CD4+ cells. The major cell type in the lung
responsible for the clearance of P. aeruginosa is the neutro-
phil [9, 50]. Protection achieved in the killed P. aeruginosa-
immunized animals was associated with CD4+IL-17+Th17
and rapid requirement of neutrophil in the lung [51]. The
lower bacterial burden in the liver, spleen, and blood showed
that the antibodies to bivalent flagellin could systemically dis-
rupt the dissemination of both P. aeruginosa stains in the
liver and spleen via the blood by inhibition of bacterial motil-
ity at the site of infection, which is the principal mechanism
of protection in the bloodstream infections following P. aer-
uginosa acute pneumonia model [17, 18, 52]. Although the
antibodies against type a or b flagellin completely inhibited
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Figure 10: The role of IL-17 in vaccine based protection against P. aeruginosa strains. Bivalent flagellin- (a, b), flagellin a- (c, d), and flagellin
b- (e, f) immunized mice (n = 12mice/group) were given IL-17 IgG or control IgG for 3 consecutive days prior to challenge with 2× 107 CFUs
of P. aeruginosa strains PAO1 and PAK. ∗P < 0 05 and ∗∗P < 0 01.
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the motility of the homologous strain, they also had slight
effects on the heterologous strain. The results of motility
inhibition and opsonophagocytic activities indicated that
the protective effect of antibodies against either type a or b
flagellin is strain specific. Passive transfer of bivalent flagellin
antisera protected mice against infection with both flagel-
lated strains of P. aeruginosa. The achieved results are also
consistent with several investigations that employed a burn
wound model to show that passive immunization with anti-
bodies raised to type a or b flagellin protects the infected mice
with the homologous strain [53, 54]. The protection provided
by antibodies raised against flagellin is highly type specific,
and the presence of antibodies to both flagellin types is criti-
cal. Thus, antibodies against bivalent flagellin showed a great
activity against two different P. aeruginosa strains and did
not interfere with the individual components for improving
the opsonophagocytic killing and immobilizing different
flagellated strains of P. aeruginosa. Hence, immunotherapy
with the antibodies to bivalent flagellin is more successful
in providing homologous and heterologous protection than
therapy with antibodies raised to each monovalent type a or
b flagellin. Also, immunization with our novel bivalent flagel-
lin vaccine does not interfere with the individual components
in improving survival or induction of protective antibodies.
We acknowledge that our protective efficacy data are con-
trary to Campodonico et al. [23], who exposed that antibod-
ies against type a or b flagellin had a low protective activity
against the homologous strain and no activity against the het-
erologous strain. It seems feasible that the apparent data dis-
crepancy might be explained by our approach using the full-
length type a and b flagellins as the target antigen of the
study. In addition, Campodonico et al. separately examined
the effects of type a and b flagellins but did not assess bivalent
flagellin [23]. Our finding that antibodies against type a or b
flagellin show high activity against homologous strains and
low activity against a heterologous strain is contrary to a
recent report [23], in which it was shown that antitype a fla-
gellin antibodies against homologous P. aeruginosa strain
have low opsonic killing activity and no killing activity. They
also reported that type b flagellin antibodies have no opsonic
killing activity against either homologous or heterologous
strain [23]. The apparent discrepancy may partially be
explained by utilizing a mixture of full-length type a and b
flagellins (containing N′and C′-terminal domains) as immu-
nogen, rather than flagellin subunits, and might account for
the protective antibody response observed in our study. It is
also worth mentioning that several reports have shown that
both N′- and C′-termini of flagellin protein have proinflam-
matory motifs [55, 56] and both trigger activation of the
innate immune response via TLR5 that enhances protective
inflammatory response and enhance recruitment of PMNs
and facilitate Pseudomonas clearance postinfection [57].
Also, previous studies have shown that flagellin mutant bac-
teria elicited severe mucosal damage by a mechanism that
also appears to involve the induction of apoptosis in the epi-
thelial cells via inhibition of NF-κB activation [58, 59]. The
TLR5 activation via flagellin may prevent bacteria to evade
the host’s innate immune responses and alter the level of tis-
sue damage associated with late-stage bacterial infection [60].
After colonization, P. aeruginosa downregulates the expres-
sion levels of flagella to evade from the TLR5-mediated host’s
innate immune activation [61]. H. pylorimay have evolved to
express inactive flagellin to prevent activation of the TLR5-
mediated host’s mucosal immunity, enabling persistent
infection in the stomach epithelia [62]. Also, Campodonico
et al.’s 2011 report demonstrated that conjugation of poly-
mannuronic acid (PMA) to type a flagellin enhanced its
immunogenicity via TLR5, indicating desirable protective
antibodies were elicited and conserved mechanism of innate
immune resistance to P. aeruginosa [63]. These observations
have important implications for use of flagellin vaccine
rather than flagella against flagellated pathogens. It seems
that activation of TLR5 may induce the protective immunity
against P. aeruginosa and decrease the risk to acquire
infections from other flagellated bacteria that activate
TLR5 [23, 63]. Lastly, we acknowledge that our findings are
contrary to the 2010 report [23], which concluded that fla-
gella are a better candidate to provide protection against
infection because they observed that antitype a flagellin and
antitype b flagellin antibodies have poor protective activity
against homologous or heterologous P. aeruginosa strains.
Several reports, however, have demonstrated that flagellin-
induced antibodies raised against a or b type flagellins
have protective activity in various murine infection models
[53, 64, 65]. Indeed, one novel feature of our approach is tar-
geting both domains of full-length type a and b flagellins, as
target antigen, protective anti-flagellin antibodies, as well as
inducing CD4+IL-17+Th17 cell response among immunized
mice indicating an active clonal expansion and a neutrophil
response that leads to higher survival (protective) rates
among immunized mice than control mice.
It is also worth indicating that the active immunization
with type a or b flagellin provided significantly protected
mice against the heterologous strain than passive therapy
with antibodies raised to type a or b flagellin. This phenom-
enon indicated that CD4+IL-17+Th17 cell-mediated immune
response might be responsible for the anti-infection activity
afforded by the bivalent flagellin when antiopsonophagocytic
killing and antimotility antibody levels were low. Also, in vivo
CD4+ T cell depletion during immunization diminished the
bivalent flagellin or type a or b flagellin vaccine-based protec-
tion against P. aeruginosa infection. However, the depletion
of CD8 lymphocytes showed no abrogation of the anti-
infection activity against the P. aeruginosa strains. The result
of present study demonstrated the fact that both adaptive
(CD4+ T cells and antibodies) and innate (macrophage and
neutrophil) effectors are required for protective immunity
against P. aeruginosa strains. T cell proliferation and IL-17
secretion response assays were confirmatory data showing
the evidence for a heterologous T cell response among immu-
nized flagellin a or b mice indicating an active clonal expan-
sion and a neutrophil response that leads to higher survival
(protective) rates among immunized mice than control mice.
A recent study demonstrated that protection mediated by
PopB immunization against P. aeruginosa pneumonia is
associated with increased IL-17 cytokine whereas antisera
to PopB had neither opsonophagocytic nor anticytotoxic
activity [9]. An important feature of a desirable vaccine for
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P. aeruginosa is the ability to induce IL-17 for rapid recruit-
ment of neutrophils to the site of infection, where they can
mediate opsonophagocytic bacterial killing. In a recent
research [25], we demonstrated that bivalent flagellin vaccine
could confer protection against burn wound infection with
different flagellated strains of P. aeruginosa, by eliciting an
effective humoral immune response, including improved
opsonophagocytic killing and an immobilization of the path-
ogen at the wound site. Following burn injury, the failure of
local and systemic cellular immune responses allows patho-
genic bacteria to disseminate systemically from the site of
infection to the bloodstream and easily escalate into sepsis.
Thus, it seems that protective immune response against P.
aeruginosa burn wound infection is mediated by opsonic
antibodies. Hence, flagellin is a unique feature because of its
ability to induce both cellular and humoral immune
responses, which in turn provides protection against different
P. aeruginosa infections.
Taken together, these results offer evidence that bivalent
flagellin vaccine can confer protection against different flag-
ellated strains of P. aeruginosa infection in a burn wound
model by eliciting effective cellular and humoral immune
responses, including induction of IL-17 and improved opso-
nophagocytic killing. Thus, reducing the systemic pathogen
dissemination caused an increase in the survival of mice
infected with P. aeruginosa. Moreover, these data further
confirmed that targeting both types of flagellin with antibod-
ies resulted in significantly improved efficacy in comparison
with each monovalent antigen with the potential of broaden-
ing the coverage against P. aeruginosa strains which might
not express one of the two targets. We maintain optimism
that an effective P. aeruginosa bivalent flagellin vaccine may
eventually be developed and tested in humans toward reduc-
ing the morbidity and mortality associated with lung infec-
tions caused by P. aeruginosa.
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